加速阿片类药物减量以减少新生儿阿片戒断综合征的药理暴露:一项随机临床试验
这项实用盲法多中心随机试验纳入≥36周接受吗啡或美沙酮治疗新生儿阿片戒断综合征(NOWS)的新生儿,比较15%与10%递减减量方案。因入组缓慢提前终止,189例随机分组;
要点
- 15%递减方案耐受性良好,两组不良事件均少。
- 试验因入组缓慢提前关闭,共189例随机分组。
核心结论
- 使用15%递减的加速减量方案治疗NOWS,与10%递减相比耐受性良好且阿片治疗天数更少。
研究设计与样本
- 实用盲法随机多中心试验,纳入≥36周胎龄、接受吗啡或美沙酮作为NOWS主要药物治疗的新生儿。
- 新生儿按方案驱动减量,阿片剂量分别以15%或10%递减,鼓励每24小时减量,若NOWS症状加重则恢复前一剂量。
- 为保持盲法,15%递减方案最后3个剂量水平为安慰剂。
- 因入组缓慢提前关闭试验;共189例随机分组,15%递减组98例(51.9%),10%递减组91例(48.1%)。
主要发现
- 15%递减组平均胎龄38.8±1.2周、男性59.8%;10%递减组平均胎龄38.8±1.3周、男性61.5%。
- 吗啡是最常用的药物。
- 意向性分析纳入除15%递减组4例退出外的所有婴儿。
- 两组不良事件均少。
关键数值与推荐
- 15%递减方案:阿片剂量每次递减15%,鼓励每24小时减量,症状加重时恢复前一剂量,最后3个剂量水平为安慰剂。
- 10%递减方案:阿片剂量每次递减10%,鼓励每24小时减量,症状加重时恢复前一剂量。
- 主要结局为从首次减量剂量至停止阿片治疗的阿片治疗天数。
临床怎么用
- 对于接受吗啡或美沙酮治疗的NOWS新生儿,可考虑采用15%递减的加速减量方案以减少阿片暴露天数。
- 减量过程中若NOWS症状加重,应恢复前一剂量。
局限性
- 因入组缓慢导致试验提前关闭。
- 15%递减组有4例婴儿退出,未纳入意向性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine if newborns receiving morphine or methadone as the primary pharmacologic treatment for neonatal opioid withdrawal syndrome (NOWS) tolerate and receive fewer days of opioid using an accelerated wean protocol (15% decrements) compared with using a slower wean protocol (10% decrements). STUDY DESIGN: Newborns ≥36 weeks of gestation receiving morphine or methadone for NOWS were enrolled in a pragmatic blinded, randomized multicenter trial. Newborns underwent protocol-driven weaning with decreasing opioid doses of either 15% or 10% decrements. Weaning was encouraged every 24 hours, and if signs of NOWS worsened, the preceding dose was resumed. To maintain blinding, the last 3 dose levels of the 15% decrements were placebo. The primary outcome was the number of days of opioid treatment from the first weaning dose to cessation of opioids. RESULTS: Slow enrollment prompted early trial closure; 189 newborns were randomized, 98 (51.9%) to 15% decrements (mean ± SD, 38.8 ± 1.2 weeks gestation, 59.8% male) and 91 (48.1%) to 10% decrements (38.8 ± 1.3 weeks gestation, 61.5% male). Morphine was used most commonly. Intention-to-treat analysis included all but 4 infants withdrawn in the 15% decrement group. The durations of opioid treatment during weaning were 8.2 (7.2, 9.5) (adjusted mean [95% CI]) and 11.2 (9.7, 12.9) days for 15% and 10% decrement groups, respectively (P < .001). Adverse events were few in both groups. CONCLUSION: Pharmacologic treatment of NOWS using an accelerated wean protocol (15% decrements) was well tolerated with fewer days of opioid treatment compared with 10% decrements. TRIAL REGISTRATION: ClinicalTrials.gov number: NCT04214834.
引用
- Laptook AR, Czynski A, Chahine R, et al. Accelerated Weaning of Opioids to Reduce Pharmacologic Exposure for Neonatal Opioid Withdrawal Syndrome: A Randomized Clinical Trial. J Pediatr. 2026. PMID: 41554434. doi:10.1016/j.jpeds.2026.114992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。